1 – 15 of 15
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
- 2022
-
Mark
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population : A Multicenter Study
(
- Contribution to journal › Article
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
(
- Contribution to journal › Article
-
Mark
Noninvasive detection of any-stage cancer using free glycosaminoglycans
(
- Contribution to journal › Article
- 2021
-
Mark
Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2018
-
Mark
Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register
(
- Contribution to journal › Article
-
Mark
Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
(
- Contribution to journal › Article
-
Mark
Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative
(
- Contribution to journal › Article
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
(
- Contribution to journal › Article
- 2016
-
Mark
Årsrapport 2015 från Nationella Bröstcancerregistret
2016)(
- Book/Report › Report
- 2013
-
Mark
Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study
(
- Contribution to journal › Article
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
- 2011
-
Mark
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
(
- Contribution to journal › Article